Godavari Biorefineries reported a consolidated net loss of Rs 15.2 crore for Q2 FY27, improving from the Rs 41.6 crore loss in the same quarter last year. Revenue rose to Rs 549.8 crore, driven by strong performance in the bio-based chemicals segment. However, the integrated sugar and ethanol business faced headwinds from policy changes and feedstock volatility, leading to negative segment margins. The company is pivoting toward grain-based production to adapt to evolving government ethanol procurement policies.
Godavari Biorefineries Q2 FY27 Results
Revenue grew to Rs 549.8 crore while net loss narrowed to Rs 15.2 crore.
Reader Takeaway: Strong growth in bio-based chemicals is offset by significant pressure on sugar and ethanol segment margins.
What just happened
Godavari Biorefineries posted its financial results for the quarter ended September 30, 2026. The company reported a total revenue of Rs 549.8 crore, a notable increase from Rs 434.4 crore in the year-ago period. While the company remains in a net loss position of Rs 15.2 crore, this is a distinct improvement over the Rs 41.6 crore loss reported in Q2 FY26. EBITDA turned positive at Rs 10.9 crore compared to a loss of Rs 4.4 crore in the previous year.
Why this matters
The company is currently navigating a major shift in the national Ethanol Supply Year (ESY) policy. With the exclusion of sugarcane juice and B-heavy molasses from ethanol production, the company is aggressively transitioning to grain-based feedstock. The commission of a new grain-based distillery in June 2026 marks a strategic pivot to stabilize production despite lower procurement rates for corn-based ethanol.
Segment Performance
The bio-based chemicals segment emerged as the primary growth engine, with revenue increasing 39% YoY to Rs 204.2 crore and EBITDA margins expanding to 10.8%. Conversely, the Integrated Sugar, Co-generation & Ethanol segment continues to struggle, recording negative EBITDA margins of 2.6%. This is attributed to higher manufacturing costs and restricted access to preferred feedstocks under the new policy framework.
Risks to watch
Management highlighted significant volatility in maize prices due to monsoon-linked supply fluctuations. Furthermore, the reduction in corn-ethanol procurement rates to Rs 68.86/L poses a risk to the future profitability of tender participation. The company also continues its pharmaceutical diversification, with Phase I trials for its lead molecule complete and preparations for Q3 FY27 efficacy trials underway.
What to track next
Investors should monitor the company's ability to maintain chemical segment margins and the successful scaling of grain-based ethanol operations as the company navigates the current policy transition.